Pishvaian, M. J., Blais, E. M., Matrisian, L. M., Brody, J. R., Thach, D., Arbeloa, P. M. D., Rocha, F. G., Chuy, J. W., Wadlow, R. C., Hendifar, A. E., Petricoin, E. (2025). Validation of PDACai v2.0 in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.776